Takeda GC reports 191,280 RSU award on Form 3

TAKEDA PHARMACEUTICAL CO LTD Global General Counsel Natalie Anne Marie Furney filed an initial ownership report showing an award of 191,280 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD Global General Counsel Natalie Anne Marie Furney filed an initial ownership report showing an award of 191,280 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share.

The RSUs vest in three equal-time tranches: 63,758 on July 1, 2026, 63,758 on July 1, 2027 and 63,764 on July 1, 2028.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Furney Natalie Anne Marie

Role Global General Counsel

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 191,280 shares (Direct)

Footnotes (1)

1. F1. Represents an award of RSUs. Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (63,758 shares), July 1, 2027 (63,758 shares) and July 1, 2028 (63,764 shares).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Takeda (TAK) Global General Counsel report in this Form 3?

Takeda’s Global General Counsel Natalie Anne Marie Furney reports an award of 191,280 RSUs in her initial ownership filing. Each RSU gives a contingent right to receive one American Depositary Share, subject to the specified vesting schedule through 2028.

How many Takeda (TAK) RSUs were awarded and how do they vest?

Natalie Anne Marie Furney was awarded 191,280 RSUs. They vest in three tranches: 63,758 RSUs on July 1, 2026, 63,758 on July 1, 2027, and 63,764 on July 1, 2028, according to the disclosed schedule.

What does each RSU in the Takeda (TAK) award represent?

Each RSU in the award represents a contingent right to receive one American Depositary Share of Takeda Pharmaceutical. The shares are deliverable only as the RSUs vest on the specified July 1 dates in 2026, 2027 and 2028.

Does the Takeda (TAK) Form 3 show any open-market buying or selling?

The Form 3 does not show any open-market buying or selling activity. It reports an award of 191,280 RSUs, which are compensation-related units that vest over time rather than immediate purchases or sales in the market.

Who is the reporting person in this Takeda (TAK) insider ownership filing?

The reporting person is Natalie Anne Marie Furney, who serves as Takeda Pharmaceutical’s Global General Counsel. The filing records her initial ownership position through an award of restricted stock units tied to American Depositary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:18 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Furney Natalie Anne Marie

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	191,280(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of RSUs. Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (63,758 shares), July 1, 2027 (63,758 shares) and July 1, 2028 (63,764 shares).

Remarks:

Power of Attorney Exhibit 24

	/s/ Max Heuer, by power of attorney, for Natalie Furney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)